Determination of EC50 of ropivacaine for postoperative analgesia under general anesthesia combined with single interscalene brachial plexus block

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026099

Enrollment

Unknown

Registered

2019-09-21

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

shoulder disease

Interventions

Control group:saline injection

Group 1:0.2% ropivacaine injection

Group 2:0.375% ropivacaine injection

Group 3:0.5% ropivacaine injection

Eligibility

Sex/Gender

Male

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective shoulder arthroscopy, aged 18-79 years, BMI 18~28 kg/m2, ASA physical status I or II were included.

Exclusion criteria

Exclusion criteria: contraindicated to nerve block, failure block, pulmonary disease history, obstructive sleep apnea-hypopnea syndrome (OSAHS), chronic pain history, pre-existing diaphragm dysfunction, puncture site infection, allergy to local anaesthetics, coagulopathy, surgery time 3h, change of surgery type.

Design outcomes

Primary

Measure	Time frame
VAS;	—

Secondary

Measure	Time frame
FEV1;FVC;motor function of hand;diaphragm movement;	—

Countries

China

Contacts

Public ContactHAIYAN AN

Peking University People's Hospital

anhaiyan76@163.com+86 13521553036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026